In May, the FDA granted key approvals to treatments across the oncology autoimmune, and respiratory disease categories. Approvals include AbbVie’s Emrelis in non-small cell lung cancer, Avmapki Fakzynja Co-Pack in ovarian cancer, and GSK’s Nucala in chronic obstructive pulmonary disease. Other notable approvals are plaque psoriasis for Zoryve topical foam 0.3%, and Novavax’s Nuvaxovid (COVID-19 Vaccine, Adjuvanted) to prevent COVID-19. The FDA also approved Yutrepia, a novel prostacyclin analog inhalation powder for severe lung diseases and Alcon’s Tryptyr ophthalmic solution for dry eye disease.